Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains

  • Carcas, Antonio J.
  • Sevillano Fernández, David
  • González Hidalgo, Natalia
  • Alou Cervera, Luis
  • Gómez Gil, Rosa
  • Muñoz, Mario
  • Llanos, Lucía
  • Sánchez Villanueva, Rafael J.
  • Gonzalez Parra, Emilio
  • Giménez, María José
  • Aguilar, Lorenzo
Objectives: Bacterial viability and enrichment of resistance resulting from three different amikacin administration schedules with respect to haemodialysis (HD) were assessed against three OXA-48-producing Klebsiella pneumoniae isolated during an outbreak in a Spanish hospital. Methods: A previously described two-compartment dynamic system was used. Three possible amikacin administration schedules were simulated: (i) haemodialysis immediately after amikacin infusion (pre-HD); (ii) infusion immediately after haemodialysis (post-HD); and (iii) infusion at 50% interdialytic period. Amikacin standard dose (SD) and double dose (DD) were simulated for each schedule. Values of Cmax/MIC, Cmax/MPC (mutant prevention concentration), AUC0-48h/MIC, AUC0-48h/MPC and %TMSW (percentage of time that the concentration was inside the mutant selection window) were determined with experimental data and were correlated with the area under the bacterial killing curve of the total population and the resistant subpopulation. Results: Both with SD and DD, the pre-HD schedule resulted in increases at 48h in bacterial counts of the total population at the expense of enrichment of pre-existing resistant subpopulations from 12h onwards for all strains. The estimated %TMSW that prevented enrichment of resistant mutants was <61.5%. The AUC0-48h/MPC (with values of ≈40 being associated with countering of increases in resistant subpopulations) was better than the %TMSW as a predictive parameter. Conclusion: This study showed that the longest times concentrations were above the MPC (i.e. highest AUC0-48h/MPC, lowest %TMSW), the lowest enrichment of resistant subpopulations. This implies use of the highest possible amikacin dose (limited by toxicity) and post-HD as the best administration schedule.
Repisalud
Publicación Artículo científico (JournalArticle)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

  • Cedena, M Teresa
  • Rapado, Inmaculada
  • Santos-Lozano, Alejandro
  • Ayala, Rosa
  • Onecha, Esther
  • Abaigar, María
  • Such, Esperanza
  • Ramos, Fernando
  • Cervera, José
  • Díez-Campelo, María
  • Sanz, Guillermo
  • Rivas, Jesús Hernández
  • Lucía, Alejandro
  • Martinez-Lopez, Joaquin
We evaluated the association of mutations in 34 candidate genes and response to azacitidine in 84 patients with myelodysplastic syndrome (MDS), with 217 somatic mutations identified by next-generation sequencing. Most patients (93%) had ≥1 mutation (mean=2.6/patient). The overall response rate to azacitidine was 42%. No clinical characteristic was associated with response to azacitidine. However, total number of mutations/patient was negatively associated with overall drug response (odds ratio [OR]: 0.56, 95% confidence interval [CI]: 0.33-0.94; p=0.028), and a positive association was found for having ≥1 mutation in a DNA methylation-related gene: TET2, DNMT3A, IDH1 and/or IDH2 (OR: 4.76, 95%CI: 1.31-17.27; p=0.017). Mutations in TP53 (hazard ratio [HR]: 3.88; 95%CI: 1.94-7.75) and EZH2 (HR: 2.50; 95%CI: 1.23-5.09) were associated with shorter overall survival. Meta-analysis of 6 studies plus present data (n=815 patients) allowed assessment of the association of drug response with mutations in 9 candidate genes: ASXL1, CBL, EZH2, SF3B1, SRSF2, TET2, DNMT3A, IDH1/2 and TP53. TET2 mutations predicted a more favorable drug response compared with 'wild-type' peers (pooled OR: 1.67, 95%CI: 1.14-2.44; p=0.01). In conclusion, mutations in the DNA methylation pathway, especially TET2 mutations, and low number of total mutations are associated with a better response to azacitidine.
Repisalud
Publicación Artículo científico (JournalArticle)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

  • Onecha, Esther
  • Linares, Maria
  • Rapado, Inmaculada
  • Ruiz-Heredia, Yanira
  • Martinez-Sanchez, Pilar
  • Cedena, Teresa
  • Pratcorona, Marta
  • Oteyza, Jaime Perez
  • Herrera, Pilar
  • Barragan, Eva
  • Montesinos, Pau
  • Vela, Jose Antonio Garcia
  • Magro, Elena
  • Anguita, Eduardo
  • Figuera, Angela
  • Riaza, Rosalia
  • Martinez-Barranco, Pilar
  • Sanchez-Vega, Beatriz
  • Nomdedeu, Josep
  • Gallardo, Miguel
  • Martinez-Lopez, Joaquin
  • Ayala, Rosa
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10-4 for single nucleotide variants and 10-5 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing-determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P=0.005) and lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P=0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

  • Beltrán-Pavez, C.
  • Gutiérrez-López, M.
  • Rubio-Garrido, M.
  • Valadés-Alcaraz, A.
  • Prieto, L.
  • Ramos, J.T.
  • Jiménez De Ory, S.
  • Navarro, M.
  • Díez-Romero, C.
  • Pulido, F.
  • Valencia, E.
  • Holguín, Á.
  • Mellado, M.J.
  • Escosa, L.
  • García Hortelano, M.
  • Sainz, T.
  • González-Tomé, M.I.
  • Rojo, P.
  • Blázquez, D.
  • Prieto-Tato, L.
  • Epalza, C.
  • Ramos, J.T.
  • Guillén, S.
  • Navarro, M.L.
  • Saavedra, J.
  • Santos, M.
  • Santiago, B.
  • Aguilera-Alonso, D.
  • Jiménez De Ory, S.
  • Carrasco, I.
  • Roa, M.Á.
  • Penín, M.
  • Martínez, J.
  • Badillo, K.
  • Oñate, E.
  • Pocheville, I.
  • Garrote, E.
  • Colino, E.
  • Gómez Sirvent, J.
  • Garzón, M.
  • Román, V.
  • Angulo, R.
  • Neth, O.
  • Falcón, L.
  • Terol, P.
  • Santos, J.L.
  • Moreno, D.
  • Lendínez, F.
  • Peromingo, E.
  • Uberos, J.
  • Ruiz, B.
  • Grande, A.
  • Romero, F.J.
  • Pérez, C.
  • Lillo, M.
  • Losada, B.
  • Herranz, M.
  • Bustillo, M.
  • Collado, P.
  • Couceiro, J.A.
  • Vila, L.
  • Calviño, C.
  • Piqueras, A.I.
  • Oltra, M.
  • Gavilán, C.
  • Montesinos, E.
  • Dapena, M.
  • Álvarez, C.
  • Jiménez, B.
  • Andrés, A.G.
  • Marugán, V.
  • Ochoa, C.
  • Alfayate, S.
  • Menasalvas, A.I.
  • Ruiz Del Prado, Y.
  • Soler-Palacín, P.
  • Frick, M.A.
  • Mur, A.
  • López, N.
  • Méndez, M.
  • Mayol, L.
  • Vallmanya, T.
  • Calavia, O.
  • García, L.
  • Coll, M.T.
  • Pineda, V.
  • Rius, N.
  • Dueñas, J.
  • Fortuny, C.
  • Noguera-Julián, A.
  • Bernardino, I.
  • Montes, M.L.
  • Valencia, E.
  • Rubio, R.
  • Pulido, F.
  • Bisbal, O.
  • Gaspar Alonso, G.
  • Berenguer, J.
  • Díez, C.
  • Aldamiz, T.
  • Montilla, P.
  • Bermúdez, E.
  • Valerio, M.
  • Sanz, J.
  • Arponen, S.
  • Gimeno, A.
  • Cervero, M.
  • Torres, R.
  • Moreno, S.
  • Pérez, M.ªJ.
  • Ryan, P.
  • Troya, J.
  • Sanz, J.
  • Losa, J.
  • Gómez, R.
  • Iribarren, J.A.
  • Rodríguez, F.
  • Pascual, L.
  • Aramburu, M.J.
  • Goikoetxea, A.J.
  • Aguirrebengoa, L.
  • Muñoz, J.
  • Ibarra, S.
  • Hernández, M.
  • Gómez Sirvent, J.L.
  • Rodríguez, J.
  • Cárdenes, M.Á.
  • López-Cortés, L.F.
  • Roca, C.
  • Llaves, S.
  • Ríos, M.J.
  • Rodríguez, J.
  • Palomo, V.
  • Pasquau, J.
  • García, C.
  • Hernández, J.
  • Martínez, C.
  • Rivero, A.
  • Camacho, Á.
  • Merino, D.
  • Martínez, E.
  • Mateos, F.
  • Blanch, J.J.
  • Torralba, M.
  • Arazo, P.
  • Samperiz, G.
  • Crusells, M.J.
  • San Joaquín, I.
  • Miralles, C.
  • Ocampo, A.
  • Pousada, G.
  • Mena, Á.
  • Montero, M.
  • Salavert, M.
  • Cuéllar, S.
  • Galindo, M.J.
  • Ferrando, R.
  • Portilla, J.
  • Portilla, I.
  • Gutiérrez, F.
  • Masiá, M.
  • Robledano, C.
  • Adsuar, A.
  • Hinojosa, C.
  • Bachiller, P.
  • Abadía, J.
  • Mostaza, J.L.
  • Pérez, R.
  • Galera, C.
  • Albendín, H.
  • Pérez, A.
  • Blanco, J.R.
  • Burgos, J.
  • Torres, B.
  • Lazzari, E.
The aim of this transversal study was to describe the virological and immunological features of HIV-infected youths transferred from pediatric to adult care units since 1997 vs. the non-transferred patients from the Madrid Cohort of HIV-infected children and adolescents in Spain. We included 106 non-transferred and 184 transferred patients under clinical follow-up in 17 public hospitals in Madrid by the end of December 2017. Virological and immunological outcomes were compared in transferred vs. non-transferred patients. ART drug resistance mutations and HIV-variants were analyzed in all subjects with available resistance pol genotypes and/or genotypic resistance profiles. Among the study cohort, 133 (72.3%) of 184 transferred and 75 (70.7%) of 106 non-transferred patients had available resistance genotypes. Most (88.9%) of transferred had ART experience at sampling. A third (33.3%) had had a triple-class experience. Acquired drug resistance (ADR) prevalence was significantly higher in pretreated transferred than non-transferred patients (71.8% vs. 44%; p = 0.0009), mainly to NRTI (72.8% vs. 31.1%; p < 0.0001) and PI (29.1% vs. 12%; p = 0.0262). HIV-1 non-B variants were less frequent in transferred vs. non-transferred (6.9% vs. 32%; p < 0.0001). In conclusion, the frequent resistant genotypes found in transferred youths justifies the reinforcement of HIV resistance monitoring after the transition to avoid future therapeutic failures.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

  • Onecha, Esther
  • Ruiz‐Heredia, Yanira
  • Martínez‐Cuadrón, David
  • Barragán, Eva
  • Martínez Sánchez, María Del Pilar
  • Linares Gómez, María
  • Rapado, Inmaculada
  • Perez‐Oteyza, Jaime
  • Magro, Elena
  • Herrera, Pilar
  • Rojas, José Luis
  • Gorrochategui, Julián
  • Villoria, Jesús
  • Boluda, Blanca
  • Sargas, Claudia
  • Ballesteros, Joan
  • Montesinos, Pau
  • Martínez López, Joaquín
  • Ayala Díaz, Rosa María
Refractoriness to induction therapy and relapse after complete remission are the leading causes of death in patients with acute myeloid leukaemia (AML). This study focussed on the prediction of response to standard induction therapy and outcome of patients with AML using a combined strategy of mutational profiling by next-generation sequencing (NGS, n = 190) and ex vivo PharmaFlow testing (n = 74) for the 10 most widely used drugs for AML induction therapy, in a cohort of adult patients uniformly treated according to Spanish PETHEMA guidelines. We identified an adverse mutational profile (EZH2, KMT2A, U2AF1 and/or TP53 mutations) that carries a greater risk of death [hazard ratio (HR): 3 29, P < 0 0001]. A high correlation was found between the ex vivo PharmaFlow results and clinical induction response (69%). Clinical correlation analysis showed that the pattern of multiresistance revealed by ex vivo PharmaFlow identified patients with a high risk of death (HR: 2 58). Patients with mutation status also ran a high risk (HR 4 19), and the risk was increased further in patients with both adverse profiles (HR 4 82). We have developed a new score based on NGS and ex vivo drug testing for AML patients that improves upon current prognostic risk stratification and allows clinicians to tailor treatments to minimise drug resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

  • Ayala, Rosa|||0000-0002-2699-8353
  • Rapado, Inmaculada
  • Onecha, Esther
  • Martínez-Cuadrón, David|||0000-0001-7540-4091
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Algarra Algarra, Jesus Lorenzo
  • Tormo, Mar|||0000-0001-9622-1649
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Serrano, Josefina
  • Herrera, Pilar|||0000-0002-4118-7110
  • Ramos, Fernando
  • Salamero, Olga|||0000-0003-3237-0025
  • Lavilla, Esperanza|||0000-0003-1490-0678
  • Gil, Cristina
  • López Lorenzo, José L.|||0000-0003-1502-3902
  • Vidriales, María Belén|||0000-0001-5049-3673
  • Labrador, Jorge|||0000-0002-3696-0287
  • Falantes, José Francisco|||0000-0001-8660-7038
  • Sayas, María José
  • Paiva, Bruno|||0000-0003-1977-3815
  • Barragán, Eva
  • Prosper, Felipe|||0000-0001-6115-8790
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Montesinos, Pau|||0000-0002-3275-5593
Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10 -7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis

  • Jesson, Julie|||0000-0002-9461-2520
  • Crichton, Siobhan
  • Quartagno, Matteo
  • Yotebieng, Marcel
  • Abrams, Elaine J.
  • Chokephaibulkit, Kulkanya|||0000-0002-0140-4600
  • Le Coeur, Sophie
  • Aké-Assi, Marie-Hélène
  • Patel, Kunjal|||0000-0003-0002-681X
  • Pinto, Jorge
  • Paul, Mary
  • Vreeman, Rachel
  • Davies, Mary-Ann|||0000-0001-8496-6475
  • Ben-Farhat, Jihane
  • Van Dyke, Russell
  • Judd, Ali|||0000-0003-3176-5295
  • Mofenson, Lynne|||0000-0002-2818-9808
  • Vicari, Marissa
  • Seage, George
  • Bekker, Linda-Gail|||0000-0002-0755-4386
  • Essajee, Shaffiq
  • Gibb, Diana
  • Penazzato, Martina|||0000-0001-5485-8692
  • Collins, Intira Jeannie|||0000-0003-2132-6037
  • Wools-Kaloustian, Kara
  • Slogrove, Amy
  • Powis, Kate|||0000-0002-4478-4471
  • Williams, Paige
  • Matshaba, Mogomotsi
  • Thahane, Lineo
  • Nyasulu, Phoebe
  • Lukhele, Bhekumusa
  • Mwita, Lumumba
  • Kekitiinwa-Rukyalekere, Adeodata
  • Wanless, Sebastian
  • Goetghebuer, Tessa
  • Thorne, Claire
  • Warszawski, Josiane
  • Galli, Luisa|||0000-0002-7912-3366
  • van Rossum, Annemarie M. C.
  • Giaquinto, Carlo
  • Marczynska, Magdalena
  • Marques, Laura
  • Prata, Filipa
  • Ene, Luminita
  • Okhonskaya, Lyuba
  • Navarro, Maria Luisa
  • Frick, Antoinette
  • Naver, Lars
  • Kahlert, Christian|||0000-0002-0784-3276
  • Volokha, Alla|||0000-0003-3092-2228
  • Chappell, Elizabeth|||0000-0003-1053-6434
  • Pape, Jean William
  • Rouzier, Vanessa
  • Marcelin, Adias
  • Succi, Regina
  • Sohn, Annette H.|||0000-0002-0209-3285
  • Kariminia, Azar
  • Edmonds, Andrew
  • Lelo, Patricia
  • Lyamuya, Rita
  • Ogalo, Edith Apondi|||0000-0002-7968-9394
  • Odhiambo, Francesca Akoth
  • Haas, Andreas D.|||0000-0002-4849-181X
  • Bolton, Carolyn|||0000-0001-9103-7746
  • Muhairwe, Josephine
  • Tweya, Hannock
  • Sylla, Mariam
  • D'Almeida, Marceline
  • Renner, Lorna
  • Abzug, Mark J.
  • Oleske, James
  • Purswani, Murli
  • Teasdale, Chloe
  • Nuwagaba-Biribonwoha, Harriet|||0000-0001-5131-3371
  • Goodall, Ruth
  • Leroy, Valériane|||0000-0003-3542-8616
Adolescents living with HIV are subject to multiple co-morbidities, including growth retardation and immunodeficiency. We describe growth and CD4 evolution during adolescence using data from the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) global project. Data were collected between 1994 and 2015 from 11 CIPHER networks worldwide. Adolescents with perinatally acquired HIV infection (APH) who initiated antiretroviral therapy (ART) before age 10 years, with at least one height or CD4 count measurement while aged 10-17 years, were included. Growth was measured using height-for-age Z-scores (HAZ, stunting if <-2 SD, WHO growth charts). Linear mixed-effects models were used to study the evolution of each outcome between ages 10 and 17. For growth, sex-specific models with fractional polynomials were used to model non-linear relationships for age at ART initiation, HAZ at age 10 and time, defined as current age from 10 to 17 years of age. A total of 20,939 and 19,557 APH were included for the growth and CD4 analyses, respectively. Half were females, two-thirds lived in East and Southern Africa, and median age at ART initiation ranged from <3 years in North America and Europe to.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

  • Onecha, Esther
  • Linares, Maria
  • Rapado, Inmaculada
  • Ruiz-Heredia, Yanira
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Cedena, Teresa
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Oteyza, Jaime Perez
  • Herrera, Pilar|||0000-0002-4118-7110
  • Barragán, Eva
  • Montesinos, Pau|||0000-0002-3275-5593
  • Vela, Jose Antonio Garcia
  • Magro, Elena
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Figuera, Angela
  • Riaza, Rosalia
  • Martinez-Barranco, Pilar
  • Sanchez-Vega, Beatriz
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Miguel
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ayala, Rosa|||0000-0002-2699-8353
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10 for single nucleotide variants and 10 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing-determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P=0.005) and lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P=0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials.